X. Duval, V. Journot, and C. Leport, Incidence of and Risk Factors for Adverse Drug Reactions in a Prospective Cohort of HIV-Infected Adults Initiating Protease Inhibitor--Containing Therapy, Clinical Infectious Diseases, vol.39, issue.2, pp.248-55, 2004.
DOI : 10.1086/422141

P. Bonfanti, E. Ricci, and S. Landonio, Predictors of protease inhibitor-associated adverse events, Biomedicine & Pharmacotherapy, vol.55, issue.6, pp.321-324, 2001.
DOI : 10.1016/S0753-3322(01)00070-1

F. Abad-santos, A. Carcas, and C. Ibanez, Digoxin Level and Clinical Manifestations as Determinants in the Diagnosis of Digoxin Toxicity, Therapeutic Drug Monitoring, vol.22, issue.2, pp.163-171, 2000.
DOI : 10.1097/00007691-200004000-00004

P. Mcmaster, D. Mirza, and T. Ismail, Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation, Therapeutic Drug Monitoring, vol.17, issue.6, pp.602-607, 1995.
DOI : 10.1097/00007691-199512000-00010

O. Lyass, B. Uziely, and R. Ben-yosef, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, vol.13, issue.5, pp.1037-1084, 2000.
DOI : 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z

C. Merck, Inc. Crixivan (indinavir sulfate) product monograph. West Point, 1997.

R. Murphy, J. Sommadossi, and M. Lamson, Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1, The Journal of Infectious Diseases, vol.179, issue.5, pp.1116-1139, 1999.
DOI : 10.1086/314703

J. Durant, P. Clevenbergh, and R. Garraffo, Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study, AIDS, vol.14, issue.10, pp.1333-1342, 2000.
DOI : 10.1097/00002030-200007070-00005

E. Acosta, K. Henry, and L. Baken, Indinavir Concentrations and Antiviral Effect, Pharmacotherapy, vol.124, issue.6, pp.708-720, 1999.
DOI : 10.1097/00002030-199712000-00002

D. Burger, P. Hugen, and R. Aarnoutse, Treatment Failure of Nelfinavir-Containing Triple Therapy Can Largely Be Explained by Low Nelfinavir Plasma Concentrations, Therapeutic Drug Monitoring, vol.25, issue.1, pp.73-80, 2003.
DOI : 10.1097/00007691-200302000-00011

X. Duval, F. Mentre, and C. Lamotte, Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort, Therapeutic Drug Monitoring, vol.27, issue.1, pp.63-70, 2005.
DOI : 10.1097/00007691-200502000-00013

E. Woolf, T. Au, and H. Haddix, Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching, Journal of Chromatography A, vol.692, issue.1-2, pp.45-52, 1995.
DOI : 10.1016/0021-9673(94)00608-C

G. Aymard, M. Legrand, and N. Trichereau, Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.744, issue.2, pp.227-267, 2000.
DOI : 10.1016/S0378-4347(00)00225-5

K. Brendel, M. Legrand, and A. Taburet, Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3
DOI : 10.1097/00002030-200305230-00007

J. Mandema, P. G. Welling, and F. L. Tse, Population pharmacokinetics and pharmacodynamics, in Pharmacokinetics: regulatory, industrial, academics perspectives. Library of congress, pp.411-449, 1995.

A. Racine-poon and J. Wakefield, Statistical methods for population pharmacokinetic modelling Clinical safety data management : definitions and standards for expedited reporting, Stat Methods Med Res fed regist, vol.760, issue.17, pp.63-8411284, 1995.
DOI : 10.1191/096228098670696372

K. Boubaker, P. Sudre, and F. Bally, Changes in renal function associated with indinavir, AIDS, vol.12, issue.18, pp.249-54, 1998.
DOI : 10.1097/00002030-199818000-00003

S. Brodie, M. Keller, and B. Ewenstein, Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients, AIDS, vol.12, issue.18, pp.2433-2440, 1998.
DOI : 10.1097/00002030-199818000-00012

J. Dieleman, I. Gyssens, and M. Van-der-ende, Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients, Aids, vol.13, issue.4, pp.473-481, 1999.
DOI : 10.1097/00002030-199903110-00005

C. Flexner, HIV-protease inhibitors, N Engl J Med, vol.338, pp.1281-92, 1998.

J. Kopp, K. Miller, and J. Mican, Crystalluria and Urinary Tract Abnormalities Associated with Indinavir, Annals of Internal Medicine, vol.127, issue.2, pp.119-144, 1997.
DOI : 10.7326/0003-4819-127-2-199707150-00004

G. Plosker and . Ns, Indinavir, Drugs, vol.58, issue.6, pp.1165-203, 1999.
DOI : 10.2165/00003495-199958060-00011

D. Burger, M. Siebers, and P. Hugen, Pharmacokinetic Variability Caused by Gender: Do Women Have Higher Indinavir Exposure Than Men?, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.1, pp.101-103, 2002.
DOI : 10.1097/00042560-200201010-00014

P. Bonfanti, L. Valsecchi, and F. Parazzini, Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.23, issue.3, pp.236-281, 2000.
DOI : 10.1097/00126334-200003010-00004

O. Kirk, J. Gerstoft, and C. Pedersen, Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions 17

E. Gehan and S. George, Estimation of human body surface area from height and weight, Cancer Chemother Rep, vol.54, pp.225-260, 1970.

A. Carr and D. Cooper, Adverse effects of antiretroviral therapy, The Lancet, vol.356, issue.9239, pp.1423-1453, 2000.
DOI : 10.1016/S0140-6736(00)02854-3

D. Cockcroft and M. Gault, Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976.
DOI : 10.1159/000180580

X. Duval, G. Peytavin, and I. Albert, Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients, HIV Medicine, vol.14, issue.4, pp.307-320, 2004.
DOI : 10.1097/00002030-199910010-00001

M. Mazumdar, A. Smith, and J. Bacik, Methods for categorizing a prognostic variable in a multivariable setting, Statistics in Medicine, vol.4, issue.4, pp.559-71, 2003.
DOI : 10.1002/sim.1333

E. Martinez, M. Leguizamon, and J. Mallolas, Influence of Environmental Temperature on Incidence of Indinavir???Related Nephrolithiasis, Clinical Infectious Diseases, vol.29, issue.2, pp.422-427, 1999.
DOI : 10.1086/520226

C. Solas, S. Basso, and I. Poizot-martin, High Indinavir Cmin Is Associated With Higher Toxicity in Patients on Indinavir-Ritonavir 800/100 mg Twice-Daily Regimen, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.4, pp.374-381, 2002.
DOI : 10.1097/00126334-200204010-00008

G. Gatti, D. Biagio, A. Casazza, and R. , The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring, AIDS, vol.13, issue.15, pp.2083-2092, 1999.
DOI : 10.1097/00002030-199910220-00011

S. Khoo, S. Gibbons, and D. Back, Therapeutic drug monitoring as a tool in treating HIV infection, AIDS, vol.15, issue.5, pp.171-181, 2001.
DOI : 10.1097/00002030-200100005-00021

C. Rayner, K. Galbraith, and J. Marriott, A Critical Evaluation of the Therapeutic Range of Indinavir, Annals of Pharmacotherapy, vol.1, issue.7-8, pp.1230-1237, 2002.
DOI : 10.1345/aph.1A016

C. Marzolini, A. Telenti, and L. Decosterd, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients, AIDS, vol.15, issue.1, pp.71-76, 2001.
DOI : 10.1097/00002030-200101050-00011

D. Burger, P. Hugen, and P. Reiss, Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals, AIDS, vol.17, issue.8, pp.1157-65, 2003.
DOI : 10.1097/00002030-200305230-00007